Grace Truong’s articles from Goodwin Procter LLP are most popular:
- within Food, Drugs, Healthcare and Life Sciences topic(s)
- in United States
- with readers working within the Healthcare industries
Goodwin Procter LLP are most popular:
- within Criminal Law, Strategy and Accounting and Audit topic(s)
On August 5, 2026, Moderna announced that the FDA approved mFLUSIVA (mRNA-1010), a new seasonal influenza vaccine, for use in all adults 50 years of age and older. As we previously reported, FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted that the benefits of Moderna’s mRNA-1010 outweigh its risks for adults ages 50 to 64 and adults ages 65 and older.
mRNA-1010 has been accepted for regulatory review in the European Union, Canada, and Australia. According to Moderna, regulatory submissions in additional countries are planned during 2026.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
[View Source]